CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 203 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2023. The put-call ratio across all filers is 1.16 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $831,375 | -1.3% | 20,332 | +2.0% | 0.01% | 0.0% |
| Q1 2024 | $842,737 | +0.3% | 19,937 | +0.6% | 0.01% | 0.0% |
| Q4 2023 | $840,198 | +115.5% | 19,816 | +10.9% | 0.01% | +100.0% |
| Q3 2023 | $389,927 | -30.3% | 17,862 | +1.5% | 0.00% | -40.0% |
| Q2 2023 | $559,536 | +26.6% | 17,601 | -2.9% | 0.01% | +25.0% |
| Q1 2023 | $441,898 | -20.3% | 18,118 | +3.1% | 0.00% | -20.0% |
| Q4 2022 | $554,442 | +21.6% | 17,579 | +9.1% | 0.01% | 0.0% |
| Q3 2022 | $456,000 | +8.1% | 16,119 | +1.0% | 0.01% | +25.0% |
| Q2 2022 | $422,000 | +1.0% | 15,960 | +33.7% | 0.00% | +33.3% |
| Q1 2022 | $418,000 | +10.3% | 11,940 | +2.1% | 0.00% | 0.0% |
| Q4 2021 | $379,000 | +11.1% | 11,697 | +1.2% | 0.00% | 0.0% |
| Q3 2021 | $341,000 | +53.6% | 11,560 | +33.7% | 0.00% | +50.0% |
| Q2 2021 | $222,000 | – | 8,649 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |